Tegaserod, a 5‐HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation
Top Cited Papers
Open Access
- 2 October 2001
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 15 (10) , 1655-1666
- https://doi.org/10.1046/j.1365-2036.2001.01094.x
Abstract
Aim: To investigate the efficacy and safety of tegaserod, a novel 5‐HT4 receptor partial agonist, in a randomized, double‐blind, placebo‐controlled, 12‐week treatment, multicentre study. Methods: ...Keywords
This publication has 30 references indexed in Scilit:
- Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserodGastroenterology, 2000
- Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in ratsGastroenterology, 2000
- Principles of applied neurogastroenterology: physiology/motility-sensationGut, 1999
- Impact of Irritable Bowel Syndrome on Quality of Life and Resource Use in the United States and United KingdomDigestion, 1999
- Investigations on a 5HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: Effects on gastrointestinal motility and impaired gastric emptyingGastroenterology, 1998
- Impact of irritable bowel syndrome on quality of lifeDigestive Diseases and Sciences, 1996
- Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle toneDigestive Diseases and Sciences, 1994
- “Prokinetic” Treatment of Constipation-Predominant Irritable Bowel SyndromeJournal of Clinical Gastroenterology, 1991
- CisaprideDrugs, 1988
- Treatment of chronic constipation with cisapride and placebo.Gut, 1987